DiaSorin DIASORIN COVID-19 TEST HAS RECEIVED FDA EMERGENCY USE AUTHORIZATION 20/03/2020 DiaSorin Molecular LLC, a division of DiaSorin S.p.A., has received the Emergency Use Authorization (EUA) from the FDA for their Simplexa™ COVID-19 Direct kit. The kit provides a sample-to-answer test for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, directly from nasopharyngeal swab specimens. Read the press release HOME COMPANY CLINICAL AREAS SYSTEMS COMMITTED TO EFFICIENCY NEWS EVENTS WORLDWIDE CONTACTS Diasorin Group Diasorin Molecular Luminex Corporation Legal Notices Privacy Policy Modern Slavery Act Statement DiaSorin S.p.A. - Share Capital € 55.948.257 R.E.A. 180729 Fiscal Code and Subscription to Vercelli Companies Register no 13144290155 English Italiano

DiaSorin Events Coming events Past events HOME COMPANY CLINICAL AREAS SYSTEMS COMMITTED TO EFFICIENCY NEWS EVENTS WORLDWIDE CONTACTS US Products IMMUNODIAGNOSTICS NEWS EVENTS New Labeling & Packaging Download DiaSorin app for laboratories Diasorin Group Diasorin Molecular Luminex Corporation Legal Notices Privacy Policy Modern Slavery Act Statement DiaSorin S.p.A. - Share Capital € 55.948.257 R.E.A. 180729 Fiscal Code and Subscription to Vercelli Companies Register no 13144290155 English Italiano